Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.80.
Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a research note on Thursday, October 6th. Maxim Group raised their price target on shares of Abeona Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, September 21st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research note on Friday, September 23rd. FBR & Co reaffirmed a “positive” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research note on Wednesday, October 5th. Finally, Zacks Investment Research downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 12th.
Abeona Therapeutics (NASDAQ:ABEO) opened at 6.86 on Thursday. The company’s 50-day moving average is $5.29 and its 200-day moving average is $3.44. The company’s market cap is $230.12 million. Abeona Therapeutics has a 12 month low of $2.05 and a 12 month high of $7.19.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. On average, equities research analysts expect that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.
In other Abeona Therapeutics news, Director Todd Wider bought 5,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were acquired at an average price of $5.48 per share, with a total value of $27,400.00. Following the transaction, the director now owns 75,000 shares of the company’s stock, valued at approximately $411,000. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 13.00% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sabby Management LLC increased its position in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the period. Geode Capital Management LLC increased its position in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the period. Royce & Associates LP increased its position in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares during the period. Finally, BlackRock Fund Advisors increased its position in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares during the period. 19.95% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.